var data={"title":"Sucralfate: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Sucralfate: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6993?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=sucralfate-drug-information\" class=\"drug drug_general\">see &quot;Sucralfate: Drug information&quot;</a> and <a href=\"topic.htm?path=sucralfate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Sucralfate: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24520378\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Carafate</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223521\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Sucralfate-1;</li>\n      <li>Sulcrate;</li>\n      <li>Sulcrate Suspension Plus</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062414\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Gastrointestinal Agent, Gastric or Duodenal Ulcer Treatment</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062409\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=sucralfate-drug-information\" class=\"drug drug_general\">see &quot;Sucralfate: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Peptic ulcer disease, adjunct therapy:</b> Limited data available: Infants, Children, and Adolescents: Oral: 40 to 80 mg/kg/day divided every 6 hours. Maximum dose: 1,000 mg/dose (Kliegman 2016; Nelson 1996)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Esophagitis</b> (Arguelles-Martin 1989): Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;3 months and Children &lt;6 years: Oral: 500 mg/dose four times daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;6 years: Oral: 1,000 mg/dose four times daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Dosing from a prospective trial of 75 patients (age range: 3 months to 13 years) who received sucralfate tablets (n=25), sucralfate suspension (n=25), or cimetidine (n=25) for reflux esophagitis. At the end of 8 weeks, 68% of patients receiving sucralfate tablet, 92% of patients receiving sucralfate suspension, and 79% of patients receiving cimetidine were asymptomatic. Sucralfate was well tolerated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Duodenal ulcer, treatment:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Initial treatment:</i> 1 g 4 times daily on an empty stomach for 4 to 8 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Maintenance/prophylaxis of duodenal ulcer:</i> 1 g twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling. Aluminum salt is minimally absorbed (&lt;5%); however, may accumulate in renal failure; use with caution in patients with chronic renal failure. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223498\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Carafate: 1 g/10 mL (420 mL) [contains fd&amp;c red #40, methylparaben, sorbitol; cherry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Carafate: 1 g [scored; contains fd&amp;c blue #1 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223484\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062417\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Oral: Administer on an empty stomach 1 hour before meals and at bedtime; tablet may be broken or dissolved in water before ingestion; do not administer antacids within 30 minutes of administration; shake suspension well before use </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223516\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suspension: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); do <b>not</b> freeze.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet: Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062416\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Short-term treatment of active duodenal ulcers (Oral suspension, tablet: FDA approved in adults); maintenance treatment of duodenal ulcers (Tablets: FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223573\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sucralfate may be confused with salsalate </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Carafate may be confused with Cafergot</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">For oral administration only. Fatal pulmonary or cerebral embolism has been reported following inadvertent IV administration of sucralfate.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223571\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Constipation </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Anaphylaxis, bezoar formation; hypersensitivity (urticaria, angioedema, facial swelling, laryngospasm, respiratory difficulty, rhinitis)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223504\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to sucralfate or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223488\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Hyperglycemia has been reported with sucralfate suspension in patients with diabetes; monitor glycemia closely; adjustment of antidiabetic treatment may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Duodenal ulceration: Because sucralfate acts locally at the ulcer, successful therapy with sucralfate should not be expected to alter the posthealing frequency of recurrence or the severity of duodenal ulceration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with chronic renal failure; sucralfate is an aluminum complex, small amounts of aluminum are absorbed following oral administration. Excretion of aluminum may be decreased in patients with chronic renal failure or on dialysis, increasing the risk of aluminum accumulation and toxicity (eg, aluminum osteodystrophy, osteomalacia, and encephalopathy).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tablets: Use with caution in patients with conditions that may impair swallowing (eg, recent or prolonged intubation, tracheostomy, dysphagia, history of aspiration) or other conditions that may alter gag/cough reflexes, or diminish oropharyngeal coordination or motility; aspiration with accompanying respiratory complications has been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Other warnings/precautions:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Administration: Administer sucralfate by oral route only; fatal complications, including cerebral and pulmonary emboli, have been reported with inadvertent IV administration of sucralfate.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300087\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223493\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12811&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Bictegravir: Sucralfate may decrease the serum concentration of Bictegravir.  Management: Administer bictegravir, emtricitabine, and tenofovir alafenamide under fasting conditions at least 2 hours before sucralfate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholic Acid: Sucralfate may decrease the absorption of Cholic Acid. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Digoxin: Sucralfate may decrease the serum concentration of Digoxin. Specifically, sucralfate may decrease the absorption of digoxin.  Management: Administer digoxin at least 2 hours before or at least 6 hours after sucralfate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dolutegravir: Sucralfate may decrease the serum concentration of Dolutegravir.  Management: Administer dolutegravir at least 2 hours before or 6 hours after sucralfate. Administer the dolutegravir/rilpivirine combination product at least 4 hours before or 6 hours after sucralfate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eltrombopag: Sucralfate may decrease the serum concentration of Eltrombopag.  Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of sucralfate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Furosemide: Sucralfate may decrease the serum concentration of Furosemide. Sucralfate may impair the absorption of furosemide.  Management: Avoid concomitant oral administration of furosemide and sucralfate. Separate administration by at least 2 hours. Does not apply to parenterally administered furosemide.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketoconazole (Systemic): Sucralfate may decrease the serum concentration of Ketoconazole (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levothyroxine: Sucralfate may decrease the serum concentration of Levothyroxine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May increase the serum concentration of Sucralfate. Specifically, the absorption of aluminum may be increased. Sucralfate may decrease the serum concentration of Multivitamins/Fluoride (with ADE). More specifically, sucralfate may impair the absorption of fluoride. Management: Avoid administration of aluminum-containing products, such as sucralfate, within at least 1-2 hours of fluoride administration. In patients with severe renal dysfunction, consider avoiding this combination altogether.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May increase the serum concentration of Sucralfate. Specifically, the absorption of aluminum from sucralfate may be increased, leading to an increase in the serum aluminum concentration.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphate Supplements: Sucralfate may decrease the absorption of Phosphate Supplements.  Management: This applies only to oral phosphate administration. Administering oral phosphate supplements at least 1 hour before or 2 hours after administration of sucralfate may reduce the significance of the interaction.<b> Exceptions: </b>Sodium Glycerophosphate Pentahydrate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNIDine: Sucralfate may decrease the serum concentration of QuiNIDine. Specifically, sucralfate may decrease the absorption of quinidine.  Management: Administer quinidine at least 2 hours before or at least 6 hours after sucralfate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: Sucralfate may decrease the serum concentration of Quinolones.  Management: Administer oral quinolones at least 2 hours before or 6 hours after the sucralfate dose.  Greater separation of doses may further lessen the risk for a significant interaction.<b> Exceptions: </b>LevoFLOXacin (Oral Inhalation).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulpiride: Sucralfate may decrease the serum concentration of Sulpiride.  Management: Separate administration of sucralfate and sulpiride by at least 2 hours in order to minimize the impact of sucralfate on sulpiride absorption.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: Sucralfate may decrease the absorption of Tetracyclines.  Management: Administer the tetracycline derivative at least 2 hours prior to sucralfate in order to minimize the impact of this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin D Analogs: May increase the serum concentration of Sucralfate. Specifically, the absorption of aluminum from sucralfate may be increased, leading to an increase in the serum aluminum concentration.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Sucralfate may diminish the anticoagulant effect of Vitamin K Antagonists. Sucralfate may decrease the serum concentration of Vitamin K Antagonists. Specifically, sucralfate may decrease the absorption of Vitamin K Antagonists.  Management: Administer vitamin K antagonists at least 2 hours before or at least 6 hours after sucralfate.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223495\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223507\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Sucralfate is only minimally absorbed following oral administration. Based on available data, use of sucralfate does not appear to increase the risk of adverse fetal events when used during the first trimester (Mahadevan, 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223487\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Forms a complex by binding with positively charged proteins in exudates, forming a viscous paste-like, adhesive substance. This selectively forms a protective coating that acts locally to protect the gastric lining against peptic acid, pepsin, and bile salts. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223503\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Paste formation and ulcer adhesion: 1 to 2 hours; acid neutralizing capacity: ~14 to 16 mEq/1 g dose of sucralfate</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Minimal from GI tract</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Acts locally at ulcer sites; unbound in GI tract to aluminum and sucrose octasulfate</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: None</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Primarily urine (small amounts of sulfated disaccharide)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062422\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">There is approximately 14 to 16 mEq acid neutralizing capacity per 1 g sucralfate</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10806440\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Commercial oral suspension is available (100 mg/mL).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">A 66.67 mg/mL oral suspension may be made with tablets. Add eight 1 g tablets to a 120 mL glass bottle. Add 40 mL of SWFI and allow tablets to dissolve (~2 minutes). Add 40 mL of sorbitol 70% solution and shake well. In a separate container, dissolve 2 flavor packets (Vari-Flavors; Ross Laboratories) with 10 mL of water, and swirl until dissolved then add to drug mixture. Add SWFI to make 120 mL. Label &quot;shake well&quot; and &quot;refrigerate&quot;. Use within 2 weeks. </p>\n    <div class=\"reference\">Ferraro JM. Sucralfate suspension for mouth ulcers. <i>Drug Intell Clin Pharm</i>. 1985;19(6):480.<span class=\"pubmed-id\">3839180</span></div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223506\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Carafate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g/10 mL (420 mL): $229.34</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Carafate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (100): $425.76</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Sucralfate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (100): $70.92</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223509\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Alivoato (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Alsucral (EC, FI, MY);</li>\n      <li>Alusac (UY);</li>\n      <li>Alusulin (HU);</li>\n      <li>Andapsin (SE);</li>\n      <li>Antepsin (AR, BD, DK, FI, IE, IS, IT, MT, NO, TR);</li>\n      <li>Calfate (PT);</li>\n      <li>Carafate (AU, NZ);</li>\n      <li>Ciprid (EC);</li>\n      <li>Dip (CO, EC);</li>\n      <li>Discral (MX);</li>\n      <li>Dolisec (GR);</li>\n      <li>Episan (ID);</li>\n      <li>Exinol (VE);</li>\n      <li>Gasmezol (VN);</li>\n      <li>Gastril (EC);</li>\n      <li>Gastrofait (QA);</li>\n      <li>Gastronic (BD);</li>\n      <li>Inpepsa (ID);</li>\n      <li>Iselpin (PH);</li>\n      <li>Keal (FR, LU);</li>\n      <li>Metixane (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Mucifat (ID);</li>\n      <li>Neciblok (ID);</li>\n      <li>Peptonorm (GR);</li>\n      <li>Profat (ID);</li>\n      <li>Serat (VN);</li>\n      <li>Sucrabest (LU);</li>\n      <li>Sucrafil (LK);</li>\n      <li>Sucrafilm (BR);</li>\n      <li>Sucral (PY);</li>\n      <li>Sucralfin (IT, PH);</li>\n      <li>Sucralose (AE);</li>\n      <li>Sucramal (CR, DO, GT, HN, IT, NI, PA, SV);</li>\n      <li>Sucrassyl (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Sucrate (CN, HK, LB);</li>\n      <li>Sucrate Gel (SG);</li>\n      <li>Sude (CN);</li>\n      <li>Sulcran (CL);</li>\n      <li>Sulcrate (JP);</li>\n      <li>Taxilan (ID);</li>\n      <li>Ulcafate (PK);</li>\n      <li>Ulcar (AE, BH, CY, EG, FR, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Ulcera (ID);</li>\n      <li>Ulcerfate (IN);</li>\n      <li>Ulcerlmin (JP, KR);</li>\n      <li>Ulcermin (PT);</li>\n      <li>Ulcertec (MY);</li>\n      <li>Ulcetab (ZA);</li>\n      <li>Ulcicure (QA, SA);</li>\n      <li>Ulcogant (AT, BE, CH, CZ, DE, HU, LU, NL, PE);</li>\n      <li>Ulcumaag (ID);</li>\n      <li>Ulcyte (AU);</li>\n      <li>Ulsaheal (AE, BH, IQ, JO, SA);</li>\n      <li>Ulsanic (ID, IL, JP, TH, TW, ZA);</li>\n      <li>Ulsec (BD);</li>\n      <li>Ulsicral (ID);</li>\n      <li>Unival (MX);</li>\n      <li>Urbal (ES);</li>\n      <li>Vanter (LT);</li>\n      <li>Venter (EE, HR, HU, LV, PL, RO, RU, SI, SK, UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Arg&uuml;elles-Martin F, Gonzalez-Fernandez F, Gentles MG. Sucralfate versus cimetidine in the treatment of reflux esophagitis in children. <i>Am J Med</i>. 1989;86(6A):73-76.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Carafate (sucralfate) [prescribing information]. Bridgewater, NJ: Aptalis Pharma US, Inc; 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. <i>Nelson' s Textbook of Pediatrics</i>. 20th ed. Philadelphia, PA: Saunders Elsevier; 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mahadevan U, Kane S. American Gastroenterological Association Institute technical review on the use of gastrointestinal medications in pregnancy. <i>Gastroenterology</i>. 2006;131(1):283-311.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sucralfate-pediatric-drug-information/abstract-text/16831611/pubmed\" target=\"_blank\" id=\"16831611\">16831611</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nelson WE, Behrman RE, Kliegman RM, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 15th ed. Philadelphia, PA: WB Saunders Company; 1996.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12811 Version 137.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F24520378\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F223521\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1062414\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1062409\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F223498\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F223484\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1062417\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F223516\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1062416\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F223573\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F223571\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F223504\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F223488\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300087\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F223493\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F223495\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F223507\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F223487\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F223503\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1062422\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F10806440\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F223506\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F223509\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12811|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=sucralfate-drug-information\" class=\"drug drug_general\">Sucralfate: Drug information</a></li><li><a href=\"topic.htm?path=sucralfate-patient-drug-information\" class=\"drug drug_patient\">Sucralfate: Patient drug information</a></li></ul></div></div>","javascript":null}